scPharmaceuticals (NASDAQ:SCPH – Get Rating) and Calithera Biosciences (NASDAQ:CALA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.
Insider & Institutional Ownership
53.9% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 33.7% of Calithera Biosciences shares are owned by institutional investors. 4.7% of scPharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Get scPharmaceuticals alerts:Volatility and Risk
scPharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
Profitability
This table compares scPharmaceuticals and Calithera Biosciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| scPharmaceuticals | N/A | -78.70% | -54.65% |
| Calithera Biosciences | N/A | -919.76% | -103.32% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for scPharmaceuticals and Calithera Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| scPharmaceuticals | 0 | 0 | 6 | 0 | 3.00 |
| Calithera Biosciences | 0 | 2 | 1 | 0 | 2.33 |
scPharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 107.85%. Calithera Biosciences has a consensus target price of $18.67, indicating a potential upside of 41,381.48%. Given Calithera Biosciences' higher possible upside, analysts plainly believe Calithera Biosciences is more favorable than scPharmaceuticals.
Earnings and Valuation
This table compares scPharmaceuticals and Calithera Biosciences' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| scPharmaceuticals | N/A | N/A | -$28.03 million | ($1.30) | -6.66 |
| Calithera Biosciences | $9.75 million | 0.02 | -$115.09 million | ($25.60) | 0.00 |
scPharmaceuticals has higher earnings, but lower revenue than Calithera Biosciences. scPharmaceuticals is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
scPharmaceuticals beats Calithera Biosciences on 7 of the 12 factors compared between the two stocks.
About scPharmaceuticals
(Get Rating)
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
About Calithera Biosciences
(Get Rating)
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.